Innovate Biopharmaceuticals News Releases http://ir.innovatebiopharma.com/ Innovate Biopharmaceuticals News Releases en Innovate Biopharmaceuticals Announces the Start of the First Phase 3 Clinical Trial in Celiac Disease http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-announces-start-first-phase-3 Launch of the first ever phase 3 trial in the history of celiac disease RALEIGH, N.C. , June 10, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, Mon, 10 Jun 2019 08:01:00 -0400 Innovate Biopharmaceuticals News Releases 8121 Innovate Biopharmaceuticals Announces Presentation of Three Posters Focusing on the Molecular Biology and Pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-announces-presentation-three-posters Analyst Meeting to be held at 4:30pm ET today to discuss NASH data and provide clinical updates Three posters presented at DDW 2019 highlighted the protective effect and molecular mechanism of action of larazotide acetate in pre-clinical models via myosin light chain (MLC) phosphorylation RALEIGH, Mon, 20 May 2019 09:45:00 -0400 Innovate Biopharmaceuticals News Releases 8066 Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharma-announces-analyst-event-monday-may-20-2019 RALEIGH, N.C. , May 09, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory disease, announced that it plans to host an Analyst Event on Monday, May 20, 2019 , Thu, 09 May 2019 08:01:00 -0400 Innovate Biopharmaceuticals News Releases 8041 Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-announces-closing-87-million RALEIGH, N.C. , May 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272 shares of common stock at a purchase price of $2.025 per share, for aggregate gross proceeds of Wed, 01 May 2019 16:30:00 -0400 Innovate Biopharmaceuticals News Releases 8026 Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-the-Market http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-announces-87-million-registered RALEIGH, N.C. , April 29, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced that it has entered into securities purchase agreements with certain institutional investors providing for the purchase and sale of 4,318,272 shares of common stock at a purchase Mon, 29 Apr 2019 13:19:00 -0400 Innovate Biopharmaceuticals News Releases 8016 Innovate Biopharmaceuticals Shows Larazotide is the First Drug, with its Novel Mechanism of Action of Re-normalizing the Intestinal Barrier, to Demonstrate Improvements in validated NASH Biomarkers and Endpoints in synergy with obeticholic acid, an FXR ag http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-shows-larazotide-first-drug-its Continued execution toward start of the first phase 3 celiac disease clinical trial in the current quarter with key sites for trial launch selected and active recruitment efforts underway NASH Data Presentation at Analyst Meeting at Digestive Disease Week (DDW) conference on May 20, 2019 in San Mon, 29 Apr 2019 07:35:00 -0400 Innovate Biopharmaceuticals News Releases 8006 Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-first-quarter-2019-financial-results RALEIGH, N.C. , April 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc.  (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that company executives intend to host a webcast on Monday, April Fri, 26 Apr 2019 12:59:00 -0400 Innovate Biopharmaceuticals News Releases 7981 Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-presents-oral-poster-european Selected for oral poster tour by the scientific committee in the gut microbiota section at the International Liver Congress TM 2019 of EASL Data presented as a poster showing significant effect on gut epithelial integrity thought to be key for bacterial translocation leading to NAFLD and NASH Thu, 11 Apr 2019 09:45:00 -0400 Innovate Biopharmaceuticals News Releases 7966 Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on April 29, 2019 http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-announce-first-quarter-2019 Innovate plans to provide an operational progress update, including regarding its first phase 3 celiac disease clinical trial Topline NASH preclinical data expected to be released at the Digestive Disease Week (DDW) medical conference to be held May 18-21, 2019 in San Diego RALEIGH, N.C. Tue, 02 Apr 2019 07:00:00 -0400 Innovate Biopharmaceuticals News Releases 7961 Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models http://ir.innovatebiopharma.com/news-releases/news-release-details/innovate-biopharmaceuticals-announces-collaboration-institut Innovate reiterates the start of the first Phase 3 clinical trial in celiac disease in Q2 2019 RALEIGH, N.C. , March 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and Tue, 26 Mar 2019 09:32:00 -0400 Innovate Biopharmaceuticals News Releases 7951